Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
J. Feldman, J. Bals, C. Altomare, K. S. Denis, E. C. Lam, B. M. Hauser, L. Ronsard, M. Sangesland, T. B. Moreno, V. Okonkwo, N. Hartojo, A. B. Balazs, G. Bajic, D. Lingwood, A. G. Schmidt
The paper isolates naive B cells targeting SARS-CoV-2 RBD and shows they can neutralize the virus and variants.
bioRxiv · Feb 2, 2021Immunology